{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T14:41:41Z","timestamp":1776696101512,"version":"3.51.2"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012543","name":"Youth Science Foundation of Guangxi Medical University","doi-asserted-by":"publisher","award":["GXMUYSF202525"],"award-info":[{"award-number":["GXMUYSF202525"]}],"id":[{"id":"10.13039\/501100012543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Talaromyces marneffei can cause life-threatening disseminated infection, yet the immune alterations linking STAT1 gain-of-function (GOF) variants, including the previously reported L351F site, to talaromycosis remain incompletely defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We investigated STAT1-L351F in a four-member pedigree in which disease was restricted to the proband, combining human immunophenotyping, mechanistic assays, and an in vivo infection model. Systemic immune status was assessed by serum cytokine profiling, and peripheral blood mononuclear cell (PBMC) antifungal control was quantified using CFU-based ex vivo growth assays with T. marneffei, with extension to Cryptococcus neoformans and Candida albicans. STAT1 signaling was evaluated in HEK293T cells expressing STAT1-WT or STAT1-L351F by measuring IFN-\u03b1\/\u03b2\/\u03b3-induced STAT1 phosphorylation and interferon-stimulated response element\/gamma-activated sequence (ISRE\/GAS) reporter activity. Wild-type and Stat1-L351F knock-in mice were challenged intranasally with T. marneffei and analyzed for lung fungal burden, histopathology, immune profiling, and bulk lung transcriptomics; infected Stat1-L351F mice additionally received ruxolitinib to probe the impact of JAK inhibition on infection-associated myeloid responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The proband displayed an interferon-skewed cytokine milieu, and patient PBMCs supported increased ex vivo growth of T. marneffei and C. neoformans, whereas C. albicans did not show a consistent increase. STAT1-L351F was associated with increased IFN-induced STAT1 phosphorylation and enhanced ISRE\/GAS reporter activity, consistent with a hyper-responsive interferon signaling state in this system. In vivo, female Stat1-L351F mice developed higher lung fungal burden and more severe pathology at 16 days post-infection, accompanied by reduced NKT-cell frequencies and broad transcriptomic remodeling characterized by type I interferon-biased signatures together with dysregulated myeloid\/neutrophil effector and IL-17-related programs. Ruxolitinib partially attenuated infection-associated expansion of myeloid-derived suppressor cell subsets.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Overall, STAT1-L351F was associated with impaired antifungal control, selective ex vivo permissiveness to distinct fungal pathogens, and altered IL-17-linked immune programs during T. marneffei infection, providing a multi-layered framework for understanding how dysregulated STAT1 signaling may reshape antifungal immunity across human, cell-based, and in vivo systems.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1813775","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T13:46:57Z","timestamp":1776692817000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["STAT1-L351F is associated with enhanced interferon signaling and susceptibility to Talaromyces marneffei infection"],"prefix":"10.3389","volume":"17","author":[{"given":"Yuchen","family":"Gu","sequence":"first","affiliation":[{"name":"Shenzhen Key Laboratory of Pathogen and Immunity, National Clinical Research Center for Infectious Disease, State Key Discipline of Infectious Disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology","place":["Shenzhen, China"]},{"name":"School of Medicine, Southern University of Science and Technology","place":["Shenzhen, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haimei","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Public Health, Shenzhen University Medical School","place":["Shenzhen, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiaozi","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The First Affiliated Hospital of Guangxi Medical University","place":["Nanning, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoguo","family":"Ye","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou","place":["Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongli","family":"Lian","sequence":"additional","affiliation":[{"name":"Hargen Biotechnology (Shenzhen) Co., Ltd","place":["Shenzhen, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinru","family":"Li","sequence":"additional","affiliation":[{"name":"School of Public Health, Shenzhen University Medical School","place":["Shenzhen, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingxia","family":"Liu","sequence":"additional","affiliation":[{"name":"Shenzhen Key Laboratory of Pathogen and Immunity, National Clinical Research Center for Infectious Disease, State Key Discipline of Infectious Disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology","place":["Shenzhen, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Yuan","sequence":"additional","affiliation":[{"name":"Shenzhen Key Laboratory of Pathogen and Immunity, National Clinical Research Center for Infectious Disease, State Key Discipline of Infectious Disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology","place":["Shenzhen, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The First Affiliated Hospital of Guangxi Medical University","place":["Nanning, China"]},{"name":"Key Laboratory of Basic Research on Regional Diseases, Guangxi Medical University, Education Department of Guangxi Zhuang Autonomous Region","place":["Nanning, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00051-22","article-title":"An overlooked and underrated endemic mycosis-talaromycosis and the pathogenic fungus Talaromyces marneffei","volume":"36","author":"Wang","year":"2023","journal-title":"Clin Microbiol Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/jof8020200","article-title":"Talaromyces marneffei infection: Virulence, intracellular lifestyle and host defense mechanisms","volume":"8","author":"Pruksaphon","year":"2022","journal-title":"J Fungi (Basel)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1186\/s12879-020-05260-8","article-title":"Burden of Talaromyces marneffei infection in people living with HIV\/AIDS in Asia during ART era: a systematic review and meta-analysis","volume":"20","author":"Qin","year":"2020","journal-title":"BMC Infect Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-024-01798-3","article-title":"Characteristics of endemic mycoses Talaromyces marneffei infection associated with inborn errors of immunity","volume":"45","author":"Xing","year":"2024","journal-title":"J ClinImmunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1492000","article-title":"Human inborn errors of immunity underlying Talaromyces marneffei infections: a multicenter, retrospective cohort study","volume":"16","author":"Fan","year":"2025","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"9069","DOI":"10.1038\/s41598-022-13160-x","article-title":"Clinical findings and predictive factors for positive anti-interferon-\u03b3 autoantibodies in patients suffering from a non-tuberculosis mycobacteria or Talaromyces marneffei infection: a multicenter prospective cohort study","volume":"12","author":"Qiu","year":"2022","journal-title":"Sci Rep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s2214-109x(21)00350-8","article-title":"A global call for talaromycosis to be recognised as a neglected tropical disease","volume":"9","author":"Narayanasamy","year":"2021","journal-title":"Lancet Glob Health"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa502","article-title":"Occult Talaromyces marneffei infection unveiled by the novel Mp1p antigen detection assay","volume":"7","author":"Ly","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/jof9060647","article-title":"An overview of diagnostic and management strategies for talaromycosis, an underrated disease","volume":"9","author":"Zaongo","year":"2023","journal-title":"J Fungi (Basel)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.987692","article-title":"Rapid diagnosis of Talaromyces marneffei infection by metagenomic next-generation sequencing technology in a Chinese cohort of inborn errors of immunity","volume":"12","author":"Liu","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.682350","article-title":"Case report: Disseminated Talaromyces marneffei infection in a patient with chronic mucocutaneous candidiasis and a novel STAT1 gain-of-function mutation","volume":"12","author":"Chen","year":"2021","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.08.004","article-title":"JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition","volume":"148","author":"Luo","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1186\/s12879-021-06255-9","article-title":"Clinical findings of Talaromyces marneffei infection among patients with anti-interferon-\u03b3 immunodeficiency: a prospective cohort study","volume":"21","author":"Chen","year":"2021","journal-title":"BMC Infect Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.hlife.2024.03.002","article-title":"Dysregulated STAT1 gain-of-function: Pathogen-free autoimmunity and fungal infection","volume":"2","author":"Guo","year":"2024","journal-title":"hLife"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-020-00847-x","article-title":"Human STAT1 gain-of-function heterozygous mutations: Chronic mucocutaneous candidiasis and type I interferonopathy","volume":"40","author":"Okada","year":"2020","journal-title":"J ClinImmunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-679902","article-title":"Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype","volume":"127","author":"Toubiana","year":"2016","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.654406","article-title":"Clinical relevance of gain- and loss-of-function germline mutations in STAT1: A systematic review","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/cei\/uxac106","article-title":"Inborn errors of immunity with loss- and gain-of-function germline mutations in STAT1","volume":"212","author":"Asano","year":"2023","journal-title":"Clin Exp Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.632997","article-title":"Transcriptional profiling of STAT1 gain-of-function reveals common and mutation-specific fingerprints","volume":"12","author":"Giovannozzi","year":"2021","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41525-021-00196-7","article-title":"STAT1 gain-of-function heterozygous cell models reveal diverse interferon-signature gene transcriptional responses","volume":"6","author":"Scott","year":"2021","journal-title":"NPJ Genom Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190502","article-title":"Anti-IFN-\u03b3 autoantibodies underlie disseminated Talaromyces marneffei infections","volume":"217","author":"Guo","year":"2020","journal-title":"J Exp Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01348-2","article-title":"Fungal sensing by dectin-1 directs the non-pathogenic polarization of T(H)17 cells through balanced type I IFN responses in human DCs","volume":"23","author":"Gringhuis","year":"2022","journal-title":"Nat Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41577-022-00746-9","article-title":"IL-17 and IL-17-producing cells in protection versus pathology","volume":"23","author":"Mills","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2020.00321","article-title":"Dectin-1 promotes type I and III interferon expression to support optimal antifungal immunity in the lung","volume":"10","author":"Dutta","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxz079","article-title":"Human gain-of-function STAT1 mutation disturbs IL-17 immunity in mice","volume":"32","author":"Tamaura","year":"2020","journal-title":"Int Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1646761","article-title":"Case report: Dual molecular diagnosis of gain-of-function STAT1 mutation and regulatory STAT3 variant in a patient with a hyper-IgE-like phenotype","volume":"16","author":"Yaakoubi","year":"2025","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s10875-024-01684-y","article-title":"Patients with STAT1 gain-of-function mutations display increased apoptosis which is reversed by the JAK inhibitor ruxolitinib","volume":"44","author":"Dotta","year":"2024","journal-title":"J ClinImmunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx202","article-title":"Risks of ruxolitinib in STAT1 gain-of-function-associated severe fungal disease","volume":"4","author":"Zimmerman","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.07.020","article-title":"Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations","volume":"142","author":"Forbes","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-022-01351-0","article-title":"Three adult cases of STAT1 gain-of-function with chronic mucocutaneous candidiasis treated with JAK inhibitors","volume":"43","author":"Borgstr\u00f6m","year":"2023","journal-title":"J ClinImmunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2022226","article-title":"STAT1 gain of function, type 1 diabetes, and reversal with JAK inhibition","volume":"383","author":"Chaimowitz","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1813775\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T13:47:02Z","timestamp":1776692822000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1813775\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":31,"alternative-id":["10.3389\/fimmu.2026.1813775"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1813775","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"article-number":"1813775"}}